Navigation Links
BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
Date:8/19/2007

in

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio is comprised of two approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation. Investigational product candidates include Kuvan(TM) (sapropterin dihydrochloride), a Phase 3 product candidate for the treatment of phenylketonuria (PKU), and 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease. Both products are being developed in partnership with Merck Serono, a division of Merck KgA of Darmstadt, Germany. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

About AnGes MG, Inc.

AnGes MG, Inc., a biopharmaceutical company founded in 1999, was established on an innovative discovery by researchers of Osaka University. The company specializes in research, development and practical application of genetic medicine. Current programs include the Hepatocyte Growth Factor (HGF) genetic medicine which improves blood circulation by regenerating blood vessels, and an NFkB decoy that controls various types of inflammation.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the potential approval of Naglazyme in Japan; the continued clinical development and commercialization of Naglazyme; actions
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
2. GenoLogics Announces Bioinformatics Partnership with Illumina
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
5. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
6. Inovio Biomedicals Partners to Present New Data from Two Cancer Immunotherapy Clinical Trials
7. Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Companys Investigational Drug to Treat Cocaine and Methamphetamine Addiction
8. Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
9. KineMed Presents Data Measuring Changes in Reverse Cholesterol Transport for the First Time
10. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
11. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... SANTA CLARA, Calif. , Oct. 22, 2014 /PRNewswire/ ... today announced the introduction of the cQUB™-1 (cQuest Ultrasound ... cQUB white-label ultrasound systems designed and manufactured by Cephasonics ... brand name and model number. Cephasonics will be showcasing ... 2014 being held this week in Chongqing, ...
(Date:10/22/2014)... , October 22, 2014 Investor-Edge ... Inc. (NASDAQ: FOLD ), Progenics Pharmaceuticals Inc. ... THLD ), Idera Pharmaceuticals Inc. (NASDAQ: ... Free research on these five companies can be accessed ... 21, 2014, the NASDAQ Composite ended at 4,419.48, up ...
(Date:10/22/2014)... N.J. , Oct. 22, 2014   ... a world-renowned leader in the field of infertility, ... approach to embryonic screening. The research abstract, released ... for Reproductive Medicine (ASRM) meeting in ... (CCS) and single gene defect (SGD) pre-implantation genetic ...
Breaking Medicine Technology:Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3
... -- Pharmaceutical company Hatchtech Pty Ltd has completed treatment ... confirm the efficacy of its novel head lice treatment ... the efficacy, safety and tolerability of two dose levels ... The trial consists of treating 132 healthy subjects with ...
... LYNBROOK, N.Y., Aug. 31, 2011 Auxilium Pharmaceuticals, Inc. ... and BioSpecifics Technologies Corp. (NASDAQ: BSTC ), ... all pending litigation between the Companies and announced plans ... and human and canine lipoma as well as to ...
Cached Medicine Technology:Hatchtech Completes Treatment Phase of 2b Clinical Trial of New-Generation Head Lice Treatment Deovo™ 2Hatchtech Completes Treatment Phase of 2b Clinical Trial of New-Generation Head Lice Treatment Deovo™ 3Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 2Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 3Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 4Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 5Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 6Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 7Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 8
(Date:10/22/2014)... Springfield, Va. (PRWEB) October 22, 2014 For ... way to make money; it’s an extension of her life’s ... her latest venture as the owner of FirstLight HomeCare, make ... , “It’s important to me that my work makes a ... always harbored an entrepreneurial spirit, so after much research, I ...
(Date:10/22/2014)... Shriners Hospitals for Children® and UK ... current location of Shriners Hospitals for Children - Lexington ... the University of Kentucky Albert B. Chandler Hospital. The ... owned and operated by Shriners Hospitals for Children, and ... and their families well into the future. , “The ...
(Date:10/22/2014)... With the Affordable Care Act (ACA) open enrollment period ... for Research (AIR) finds that three out of four Americans ... 42 percent say they are not likely or only somewhat ... coverage. , The AIR survey found wide gaps in Americans’ ... correctly how much they owe for a routine doctor’s visit. ...
(Date:10/22/2014)... Healthcare professionals who are looking ... at home or on-the-go via laptops, tablets or ... new, premium Seminar-on-Demand CE courses. The new courses ... 2,000 hours of CE course offerings, allowing ... With such a diverse library, there’s something for ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Lintelus, Inc., ... Sr. Vice President of Sales, will be speaking on ... Meetings Technology Expo on October 28, at the Holiday ... hosting a booth as well as a Tech Demo ... Meeting can create a more engaging event experience. , ...
Breaking Medicine News(10 mins):Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2
... TUESDAY, March 8 (HealthDay News) -- Sleep deprivation may ... consider the potential consequences of financial risks, a new ... of sleep deprivation on 29 adult volunteers who were ... in the morning after a normal night of sleep ...
... OAK BROOK, Ill. March 8, 2011 In ... GIE: Gastrointestinal Endoscopy has published a special ... issue includes a study showing that colonoscopy has prevented ... that many more could have been prevented with more ...
... with epilepsy worry more than their physicians do about the ... a recent study. In a survey, patients with epilepsy ... concern on a list of 20 potential medical or social ... the frequency of responses among concerns recorded by physicians and ...
... brain can dramatically improve life for people with severe ... that causes painful, twisting neck muscle spasms according ... Jill Ostrem, MD and Philip Starr, MD PhD at ... with cervical dystonia can be treated with medications or ...
... , TUESDAY, March 8 (HealthDay News) -- The ... Tuesday to weigh the risks and benefits of those ... manufacturers contend, can help predict a person,s risk of ... medication. A panel of FDA advisers will look ...
... March 8 (HealthDay News) -- Coal-fired power plants emit ... to public health, warns a report released Tuesday by ... one week before the U.S. Environmental Protection Agency,s deadline ... pollution from coal-fired power plants. According ...
Cached Medicine News:Health News:Sleep Deprivation May Encourage Risky Decisions 2Health News:Colonoscopy linked to decrease in colorectal cancer deaths, but many more could have been prevented 2Health News:Colonoscopy linked to decrease in colorectal cancer deaths, but many more could have been prevented 3Health News:Colonoscopy linked to decrease in colorectal cancer deaths, but many more could have been prevented 4Health News:Epilepsy-linked memory losss worries more patients than doctors 2Health News:Epilepsy-linked memory losss worries more patients than doctors 3Health News:Epilepsy-linked memory losss worries more patients than doctors 4Health News:Brain implant surgeries at UCSF dramatically improve symptoms of debilitating condition 2Health News:FDA Weighs Pros, Cons of Home Genetic Testing 2Health News:FDA Weighs Pros, Cons of Home Genetic Testing 3Health News:Report Spells Out Harms of Coal Power Plants 2
... Blood Collection Needle consists of a BD ... safety shield aligned to the bevel-up position. ... Eclipse Blood Collection Needle has its safety ... attach a secondary safety accessory. Immediate, one-handed ...
37°C incubator for DianaGel cards....
ScanGel® Incubator...
... runs up to 12 mini gels under ... gels can be poured 12 at a ... former and Mini-PROTEAN 3 multi-casting chamber, eliminating ... Ready Gel precast gels offer the convenience ...
Medicine Products: